Madison biotech firm partners to expand its therapeutics research

Nimble Therapeutics, a Madison-based biotechnology company that uses a peptide discovery platform to identify medicines for challenging-to-drug targets, is expanding its collaboration with Genentech, a member of the Roche Group, for the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas.

Under the terms of the agreement, Nimble will receive a $20 million upfront payment; near-term, preclinical, clinical, and commercial milestone payments that could exceed $1.1 billion; as well as tiered royalties. Nimble will apply its platform against multiple targets, and Genentech and Roche will be responsible for preclinical and clinical development, and commercialization of any resulting products.

InBusiness article